Abstract 218P
Background
Adenosine (ADO) is a major immunosuppressive player within the tumor micro-environment (TME), acting via A2A and A2B receptors or through the equilibrative nucleoside transporter 1 (ENT1). Quantifying ADO in the TME could help identify tumors more likely to respond to the several ADO pathway-targeting agents that have entered clinical trials. However, several limitations make ADO measurement impractical. Gene signatures have been proposed to overcome this limitation, but none truly reflects ADO content in the TME. Here, we present the first ADO gene signature based on spatial ADO quantification in human tumors and demonstrate its potential for indication selection.
Methods
Thirteen tumor biopsies from six cancer types were analyzed for ADO using quantitative mass spectrometry imaging (qMSI). A total of 183 regions of interest (ROIs) were selected based on ADO content (high vs low) and profiled by spatial transcriptomics (GeoMx DSP). ROIs were split into training (70%) and test (30%) sets. A linear mixed model adjusted for tumor type and patient was applied to the training set to identify differentially expressed genes (DEGs) in high vs low ADO regions (FDR <0.05). g:profiler was used to perform pathway enrichment. Lasso regression identified the most predictive DEGs, and the resulting gene signature predictive accuracy was evaluated using the Area Under the Receiver Operating Characteristics (AUROC) on the test set.
Results
We identified 249 DEGs when comparing high vs low ADO ROIs across tumor types. Pathway enrichment analysis revealed associations with metabolism and immune activation. Twenty-five DEGs had the highest cross-tumor predictive power, as validated in the test set (AUC = 0.905). In TCGA, the new ADO signature was higher in tumors compared to healthy tissue and showed variable expression and prognostic value across tumor subtypes.
Conclusions
We developed the first ADO signature based on ADO content in human tumors. The novel signature is a powerful tool to prioritize indications that would benefit the most from ADO-targeting drugs, and holds potential to unveil the mechanisms of ADO immunosuppression and to identify individual patients responsive to treatment.
Legal entity responsible for the study
iTeos Therapeutics.
Funding
iTeos Therapeutics.
Disclosure
S. Dekoninck, N. Rosewick, T. Sanders, L. Chaible, J. Marchante, H. Shehade, F. Strozzi, E. Houthuys, Y. McGrath, R. Marillier, M. Rossetti: Financial Interests, Personal, Full or part-time Employment: iTeos Therapeutics; Financial Interests, Personal, Stocks/Shares: iTeos Therapeutics. C. Martinoli: Financial Interests, Personal, Advisory Role: iTeos Therapeutics.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract